The negative ANSA-RAD trial, when contrasted with the positive STAMPEDE trial, demonstrates that patient selection is paramount in adjuvant therapy. The difference in outcomes was driven by risk definition, not the drug. This reinforces that "negative" trials are clinically vital for defining which patient populations do not benefit, preventing widespread overtreatment.

Despite impressive data supporting HMA/Venetoclax, its application in younger, fit patients must be cautious. The pivotal VIALE-A trial excluded key subgroups like FLT3, core binding factor, and certain NPM1 patients, for whom intensive chemotherapy remains the standard.

While neoadjuvant pembrolizumab (KEYNOTE-689) is now standard of care for resectable head and neck cancer, it carries a critical risk. During the pre-surgical treatment window, some patients may experience disease progression or toxicity that makes them ineligible for their planned curative surgery.

Even when trials like LITESPARK 022 and Keynote 564 use identical eligibility criteria, outdated staging systems result in patient populations with different underlying risks. This makes direct comparison of outcomes between trials, even for the same drug, an unfair and statistically flawed analysis that ignores the function of a control arm.

Even when testing drugs in heavily pre-treated patients, clinical trials incorporate subtle biological selection criteria. For instance, the COMPASS trial excludes patients with visceral metastases, a tactic to enrich for a population more likely to respond and avoid the most aggressive disease subtypes.

In the LEAP-010 trial, the combination arm's higher efficacy was offset by significantly greater toxicity (67% vs 38% severe adverse events). This increased treatment burden likely limited sustained therapy and prevented patients from receiving subsequent treatments, ultimately nullifying any survival benefit from improved tumor response.

The LEAP-010 trial showed a combination therapy improved tumor response and progression-free survival but failed to improve overall survival, the ultimate measure of benefit. This highlights the risk of relying on surrogate endpoints, which can be misleading, especially when a treatment adds significant toxicity.

Xevinapant's Phase III failure, after a promising Phase II trial, was partially attributed to the broader, more heterogeneous patient population. This group experienced greater toxicity than the Phase II cohort, suggesting early-phase safety profiles may not scale, ultimately compromising the efficacy of the entire treatment regimen.

The successful KEYNOTE-564 trial intentionally used a pragmatic patient selection model based on universally available pathology data like TNM stage and grade. This approach avoids complex, inconsistently applied nomograms, ensuring broader real-world applicability and potentially smoother trial execution compared to studies relying on more niche scoring systems.